65,437 trials
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 12.7; 11.0 Months — p=0.6534
HIV
Primary: Number of Participants With HIV Viral Load Suppression in Plasma — 2; 1; 84; 8 Participants
Anemia · Dialysis-dependent Chronic Kidney Disease
Primary: Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) — 10.223; 10.059; 10.165; 9.778 grams per deciliter (g/dL)
Melanoma
Primary: Objective Response Rate of CC-122 in Combination With Nivolumab — .545; 0 proportion of participants
Current Every Day Smoker
Primary: Modified Dot-probe Task — 5.49; 7.49; 2.42; 9.85 milliseconds
Obesity, Morbid
Primary: Weight Loss — 2.8; 6.4; 1.8; 8.3 Percent change
Age-related Cognitive Decline
Primary: Memory Composite Score — -0.11; -0.14; -0.13; -0.12 Z-score — p=0.50
Focus: Long-term Retention of Gadolinium-based Contrast Agent
Primary: Concentration of Total Gadolinium in Trabecular Bone — 0.335; 0.783; 0; 0 micrograms/gram
Opioid Dependence
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 2; 3; 3 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Pittsburgh Sleep Quality Index (PSQI) Score — 7.22; 5.00 score on a scale
Anesthesia, Local
Primary: The Number of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes — 41; 2 Participants
Anemia
Primary: Non-transferrin Bound Iron — 56230; 61250 ppb x hours
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 0.045 proportion of participants
Colo-rectal Cancer
Primary: Mean Physical Health of Patient at Enrollment — 77.2; 82.7 score on a scale
Transradial Angiogram
Primary: Bleeding Requiring Intervention After Initial Hemostasis Achieved — 2; 6; 3 participants — p=0.25